The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
Open accessAbstract
Vaccine against SARS-CoV-2To the Editor: Baden et al. 1 report on a phase 3 clinical trial of the mRNA-1273 vaccine against SARS-CoV-2, and they provide information on immediate injection-site reactions, which were observed in 84.2% of the participants after the first dose.The trial also showed that delayed injection-site reactions (defined in that trial as those with an onset on or after day 8) occurred in 244 of the 30,420 participants (0.8%) after the first dose and in 68 participants (0.2%) after the second dose.These reactions included erythema, induration, and tenderness.The reactions typically resolved over the following 4 to 5 days.However, these reactions were not further characterized, and links between reactions after the first dose and those after the second dose were not provided to inform clinical care.We have also observed delayed large local reactions to the mRNA-1273 vaccine, with a median onset on day 8 (range, 4 to 11) after the first dose.These reactions had a variable appearance (Fig. 1).Here, we report on a series of 12 patients with these reactions, all of which appeared near the injection site after complete resolution of the initial local and systemic symptoms associated with vaccination.Five of the reactions were grade 3 plaques (≥10 cm in diameter) (Table 1).Some patients had concurrent systemic adverse effects, and among these patients, 2 had additional skin findings.Most patients received treatment for their symptoms (e.g., with ice and antihistamines).Some patients received glucocorticoids (topical, oral, or both), and 1 patient received antibiotic therapy for presumptive cellulitis.The symptoms resolved a median of 6 days after onset (range, 2 to 11).Our suspicion of delayed-type or T-cell-medi-Downloaded from nejm.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Adverse reactions to vaccines practice parameter 2012 update
Kelso, J. M., Greenhawt, M. J., Li, J. T., Nicklas, R. A., Bernstein, D. I., Blessing-Moore, J., Cox, L., Khan, D., Lang, D. M., Oppenheimer, J., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.003 · Cited by 293
Cited by
McMahon, D. E., Amerson, E., Rosenbach, M., Lipoff, J. B., Moustafa, D., Tyagi, A., Desai, S. R., French, L. E., Lim, H. W., Thiers, B. H., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.092 · Cited by 808
Self-citationNdeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
“However, as these reactions resolved within six days, they were not a reason for concern [110].”
BackgroundChapin-Bardales, J., Myers, T., Gee, J., Shay, D. K., Marquez, P., Baggs, J., Zhang, B., Licata, C., & Shimabukuro, T. T. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.019 · Cited by 23
Metadata
- Authors
- Blumenthal, K. G., Freeman, E. E., Saff, R. R., Robinson, L. B., Wolfson, A. R., Foreman, R. K., Hashimoto, D., Banerji, A., Li, L., Anvari, S., & Shenoy, E. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04
- Volume
- 384
- Issue
- 13
- Pages
- 1273-1277
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3134328924
- Cited by
- 269
- References
- 2
- FWCI
- 19.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.